ATLANTA, Jan. 11 /PRNewswire-USNewswire/ -- This morning Michael Hohenbery issued a press release detailing the unsafe practices of Cryolife in the processing of cadaver tissue that was placed inside of his body.
Unfortunately, Cryolife has chosen to issue a press release that
contains untrue statements, similar to the untrue press comments they made
in the past. See the Federal Court Order of 27 May 2003 in the Cryolife
Securities Litigation case where the Federal District Court ruled on the
untrue press releases of Cryolife of 7 December 2001, 29 January 2002, 23
April 2002 and 24 June 2002. (In Re Cryolife Inc Securities Litigation,
United States District Court, Northern District of Georgia, Atlanta
Division, Civil Action No. 1:02-CV-1868-BBM)
In today's press release, Cryolife states:
1. CRYOLIFE: "Shortly after the infection was discovered, Cryolife
notified the FDA of the incident as it was required to do."
THE TRUTH: The clostridium infection sustained by Michael Hohenbery
from the Cryolife cadaver tissue was acknowledged by Cryolife in
writing on February 8, 2007. Cryolife made no effort to notify
other physicians or hospitals who had received tissue from this
cadaver for at least a month and the FDA reflects posting 5 months
later in the Weekly Enforcement Report a Class I recall of certain
cadaver tissue by Cryolife. A class I recall as defined by the FDA
is one in which "there is reasonable probability that the use of or
exposure to the product will cause serious health problems or
2. CRYOLIFE: "Regrettably, the lawyers representing this individual
have chosen to make untrue public statements against our company and
our tissue processing services in an effort to force us into a
monetary settlement of the case."
|SOURCE The Keenan Law Firm|
Copyright©2008 PR Newswire.
All rights reserved